Introduction
The kidney filtration barrier is composed of fenestrated endothelial cells, the glomerular basement membrane, and the podocytes. The podocyte is a terminally differentiated epithelial cell, which in concert with the rest of the filtration barrier filters solutes while retaining large-molecular weight proteins in circulation (1, 2) . Loss of kidney filtration barrier integrity results in the escape of proteins into the urine, accounting for approximately 80% of all chronic kidney disease (CKD) that afflicts over 500 million patients worldwide (3) . Despite this, over 20 years have passed since the identification of novel therapeutic targets to impact the chronic course of proteinuric kidney diseases. Inhibition of the renin-angiotensin-aldosterone axis has remained the standard of care for patients, but as the incidence and prevalence of CKD and end-stage kidney disease (ESKD) continue to rise, alternative therapies are paramount to temper the progression of proteinuric kidney diseases (4, 5) .
To identify novel pharmacological targets through mRNA profiling, Connectivity Map databases have been developed using cancer cell lines to provide gene signature-based drug candidates (6, 7) . More recently, systems pharmacology has shown the potential use of histone deacetylase inhibitors combined with angiotensinconverting enzyme inhibitors to promote a kidney protective effect (8) . Histone acetylation is governed by 2 enzymes, the histone acetyltransferases (HATs) and the histone deacetylases (HDACs), which orchestrate the addition or removal of an acetyl group on the ε amino groups of lysine residues on the histone tail (9) (10) (11) . In general, the acetylation by HAT is thought to counteract the histone's positive charge, resulting in relaxation of the chromatin structure and allowing for increased access for transcription factors to modulate their target genes. Conversely, in the presence of an HDAC, histone deacetylation preferentially suppresses transcriptional activity (9, 12) . HAT and HDAC also modulate acetyl groups on nonhistone proteins, altering their stability and biological function (13, 14) . Within the mammalian HDAC superfamily, in the genome, there are 11 proteins that are divided into 4 families (classes I, IIa, IIb, and IV), excluding sirtuins (class III), which uniquely require NAD + as a cofactor for deacetylation (15, 16) . Accumulating evidence suggests that the ubiquitously expressed class I HDACs, HDAC1 and HDAC2, are important during not only tissue development but the progression of diseases, such as cardiac hypertrophy, stroke, and Parkinson disease (17) (18) (19) .
In this study, an unbiased gene profiling of glomeruli isolated from proteinuric mice revealed novel molecular "footprints" dysregulated in proteinuric diseases. Using a computational systems biology database, we observed that the differential expression of We identified 2 genes, histone deacetylase 1 (HDAC1) and HDAC2, contributing to the pathogenesis of proteinuric kidney diseases, the leading cause of end-stage kidney disease. mRNA expression profiling from proteinuric mouse glomeruli was linked to Connectivity Map databases, identifying HDAC1 and HDAC2 with the differentially expressed gene set reversible by HDAC inhibitors. In numerous progressive glomerular disease models, treatment with valproic acid (a class I HDAC inhibitor) or SAHA (a pan-HDAC inhibitor) mitigated the degree of proteinuria and glomerulosclerosis, leading to a striking increase in survival. Podocyte HDAC1 and HDAC2 activities were increased in mice podocytopathy models, and podocyte-associated Hdac1 and Hdac2 genetic ablation improved proteinuria and glomerulosclerosis. Podocyte early growth response 1 (EGR1) was increased in proteinuric patients and mice in an HDAC1-and HDAC2-dependent manner. Loss of EGR1 in mice reduced proteinuria and glomerulosclerosis. Longitudinal analysis of the multicenter Veterans Aging Cohort Study demonstrated a 30% reduction in mean annual loss of estimated glomerular filtration rate, and this effect was more pronounced in proteinuric patients receiving valproic acid. These results strongly suggest that inhibition of HDAC1 and HDAC2 activities may suppress the progression of human proteinuric kidney diseases through the regulation of EGR1.
TetO-Cre mouse glomeruli isolated 2 weeks after completion of doxycycline induction (Figure 2A) . Analysis of the gene expression microarrays from all batches identified 100 upregulated and 88 downregulated genes in the Tln1 fl/fl Pod-rtTA TetO-Cre mice (Figure 2B and Supplemental Table 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI124030DS1). To next probe for the differentially expressed genes, we used Drug Pair Seeker (DPS) (http://www.maayanlab.net/DPS/) to identify candidate pathways and drugs that could reverse the altered gene expression (6, 7) . A generated Connectivity Map revealed that HDACs were among the most prominent pathways ( Figure 2C ), and DPS identified HDAC inhibitors as the perturbagen with potential to block these pathways (trichostatin A and VPA) (Supplemental Table 2 ). Two weeks after completion of doxycycline induction, glomeruli isolated from the Tln1 fl/fl Pod-rtTA TetO-Cre mice revealed an increase in total HDAC activity (except for the sirtuin family) when compared with controls at the end of doxycycline induction (time zero), which further increased at 2 weeks after doxycycline completion ( Figure 2D ). However, no significant increase in Hdac mRNA expression (data not shown) or protein expression was observed ( Figure 2E ). Finally, specific examination of enriched podocytes isolated from Tln1 fl/fl Pod-rtTA TetO-Cre mouse glomeruli revealed a striking increase in both HDAC1 and HDAC2 activity (Figure 2 , F and G).
VPA treatment reduces albuminuria and progression of glomerular injury. Next, we examined whether inhibition of HDAC1 and HDAC2 with VPA would stabilize albuminuria or prevent the progression of glomerulosclerosis. VPA is an FDA-approved drug that has been in use for absence seizures since 1978 (21) (22) (23) . Over the past 4 decades, observational and randomized trials have established its efficacy as an anti-epileptic, an anti-migraine, an anti-manic, and, more recently, an anti-proliferative chemotherapy adjunct (24) (25) (26) (27) . To examine the effect of VPA on glomerular injury in Tln1 fl/fl Pod-rtTA TetO-Cre mice, VPA (150 μg/d) was administrated i.p. for 4 weeks following the completion of doxycycline induction -a time point at which albuminuria was already observed ( Figure 3A and Figure 1B) . Upon VPA treatment, urinary albumin levels plateaued and the rise of plasma creatinine was reduced ( Figure 3 , B and C). Histological analysis also demonstrated improved glomerulosclerosis, tubular dilation, and interstitial fibrosis in Tln1 fl/fl Pod-rtTA TetO-Cre mice treated with VPA ( Figure 3 , D and E, quantified in G and H). Ultrastructural examination revealed reduced foot process effacement after VPA treatment in comparison with untreated mutant mice ( Figure 3F , quantified in Figure 3I ). Because of the compelling effect of VPA on progression of glomerulosclerosis in the Tln1 fl/fl Pod-rtTA TetO-Cre mice, we administered vorinostat (SAHA; 20 mg/kg body weight) -another FDA-approved HDAC inhibitor for the treatment of cutaneous T cell lymphoma (28) -to examine whether there was a class effect with HDAC inhibitors. Similarly to treatment with VPA, treatment of the mutant mice with SAHA for 4 weeks following the completion of doxycycline induction resulted in stabilized albuminuria, mitigated the rise of serum creatinine, and inhibited glomerulosclerosis and interstitial fibrosis ( Figure 4 , A-E, quantified in G and H). Ultrastructural examination of podocytes after SAHA treatment also demonstrated a reduction in foot process effacement ( Figure 4F , quantified in I). We next tested germline Pod-Tln1-KO and Pod-Dnm-DKO mice, which develop genes in microarrays from glomeruli of proteinuric mice could be influenced by increased HDAC1 and HDAC2 activity, and potentially reversed by HDAC inhibitors. To test the potential effect of HDAC inhibitors, either of the FDA-approved drugs valproic acid (VPA) and suberanilohydroxamic acid (SAHA) was administered in different genetic and glomerular injury models. Administration of these drugs alleviated the degree of proteinuria and reduced progression to glomerulosclerosis. We further observed that mice lacking podocyte-associated HDAC1 and HDAC2 were resistant to progressive glomerulosclerosis, suggesting that one potential site where HDAC inhibition exerts its beneficial effect is at the podocytes. To provide further support for the hypothesis that HDAC inhibition might be an effective strategy for the treatment of kidney disease in humans, we examined data from over 120,000 veterans participating in the Veterans Aging Cohort Study, and found a strong protective effect of VPA exposure on the decline of estimated glomerular filtration rate over time, which was most pronounced in proteinuric kidney patients. These findings were not observed with VPA comparator drugs, lamotrigine, carbamazepine, or levetiracetam, which do not inhibit HDAC activity. Collectively these results reveal a potential role of HDAC inhibitors in the therapeutic armamentarium for progressive human proteinuric kidney diseases.
Results
Bioinformatics analysis suggests that HDAC1 and HDAC2 inhibition can reverse differential gene expression in mouse glomeruli isolated from a proteinuric kidney disease model. First, we sought to generate an adult-onset mouse model of severe progressive proteinuric kidney failure, as toxin-induced models such as nephrotoxic serum (NTS), lipopolysaccharide (LPS), and adriamycin induce modest proteinuria and are often self-limited (20) . Therefore, we generated an adult genetic mouse model of proteinuric kidney disease by ablating Tln1 in podocytes in a conditional doxycycline-inducible manner that was confirmed by the absence of podocyte-specific immunoreactivity ( Figure 1A ). Littermate mice lacking the TetO-Cre gene or the Pod-rtTA gene were used as controls. Compared with control mice, Tln1 fl/fl Pod-rtTA TetO-Cre mice developed albuminuria ( Figure 1B ) and biochemical evidence of kidney failure with elevated creatinine levels ( Figure 1C Pod-rtTA TetO-Cre mice had a reduction in podocyte number by WT1 staining ( Figure 1J ) and also a loss of actin stress fibers, similarly to the germline podocyte-specific Tln1-KO mice (data not shown) (20) .
As these genetically modified mice developed podocyte loss, glomerulosclerosis, and progressive kidney failure, which is similar to progression of human glomerular diseases, we used this model to pursue differentially expressed genes following glomerular injury through RNA profiling of control and Pod-rtTA TetO-Cre glomeruli microarray ( Figure 6A ), and identified 28 genes that were potentially reversible following VPA treatment. We confirmed by reverse transcriptase PCR the group of 28 genes that were ascertained from this second microarray ( Figure 6A and Supplemental Table 3 ). Of these 28 genes, Egr1, which encodes the transcription factor early growth response 1 and has been shown to modulate the actin cytoskeleton and cell death (30) (31) (32) , was detected to be the most highly upregulated gene in Tln1 fl/fl Pod-rtTA TetO-Cre mouse glomeruli compared with control and also to be expressed in enriched primary podocytes ( Figure 6B and Supplemental Figure 6A ). We further validated that the protein expression of EGR1 was increased at the completion of doxycycline induction (time zero) (Supplemental Figure 6B ) and continued at 2 weeks after doxycycline completion, which temporally correlated with increased podocyte HDAC activity. The increased EGR1 expression observed in the Tln1 fl/fl Pod-rtTA TetO-Cre mouse glomerulus was mitigated in VPA-or SAHA-treated mice, or in mice lacking podocyte-associated Hdac1 and Hdac2 ( Figure 6C , quantified in D). EGR1 expression was also increased in glomeruli isolated from Pod-Dnm-DKO and Pod-Tln1-KO mice, which was improved following VPA treatment (Supplemental Figure 6 , C and D). To confirm the importance of EGR1 in human proteinuric disease, kidney biopsy samples from patients with focal segmental glomerulosclerosis demonstrated increased podocyte EGR1 expression ( Figure 6E , quantified in F). Furthermore, in vitro experiments using isolated primary podocytes from Pod-Cre Rosa-DTR flox mice treated with lipopolysaccharide (LPS) or protamine sulfate (PS), two agents that induce podocyte injury, resulted in increased HDAC activity and EGR1 expression, and the latter was reduced by VPA or SAHA (Supplemental Figure  6E ; and Figure 7A , quantified in B and C). To further elucidate how EGR1 expression is regulated following podocyte injury, we examined cAMP response element-binding protein (CREB) and serum response factor (SRF), which have been previously shown to bind to the Egr1 promoter (33) . A chromatin immunoprecipitation (ChIP) assay using CREB and SRF antibodies demonstrated increased CREB binding to CRE within the Egr1 promoter in LPS-or PS-treated primary podocytes, which was decreased by VPA or SAHA ( Figure 7 , D and E). SRF binding to serum response severe albuminuria and develop histological features of focal segmental glomerulosclerosis, and interstitial damage evidenced by destroyed or dilated tubular segments (20, 29) . By 6-8 weeks of age, 80%-90% of both transgenic mice died secondary to severe kidney failure. We observed robust HDAC activity in the isolated glomeruli from these 2 transgenic mice (Supplemental Figure 1A and Supplemental Figure 2A ) and thus initiated VPA treatment at 2 and 3 weeks of age, respectively, time points when albuminuria was already present. VPA treatment inhibited the progression of albuminuria and glomerulosclerosis in both mutant mice while body weight was maintained (Supplemental Figure 1 , B-D, and Supplemental Figure  2 , B-D). Treatment of Dnm-DKO and Tln1-KO mice with VPA conferred a remarkable survival benefit, likely due to the slower progression of kidney failure (Supplemental Figure 1E and Supplemental Figure 2E ). Histological analysis also displayed reduced glomerulosclerosis and interstitial fibrosis in the VPA-treated mutant mice compared with the untreated mice (Supplemental To also examine toxin-induced mouse models of podocyte injury, we treated wildtype C57BL/6 mice with rabbit anti-mouse glomerular basement membrane serum (nephrotoxic serum [NTS] ) and wild-type BALB/c mice with adriamycin, which induced glomerular total HDAC activity (Supplemental Figure 3A) . Treatment of these mice with VPA or SAHA reduced albuminuria and improved glomerular lesions that were provoked following NTS or adriamycin administration (Supplemental Figure 3 , B-E).
Deletion of Hdac1 and Hdac2 in podocytes reduces glomerulosclerosis and interstitial fibrosis in Tln1
fl/fl Pod-rtTA TetO-Cre mice. Because HDAC1 activity and HDAC2 activity were increased in enriched podocytes obtained from Tln1 fl/fl Pod-rtTA TetO-Cre mice, and because of the beneficial effect of HDAC inhibitors in the mice, we next wanted to identify whether podocyte HDAC1 and HDAC2 activation contributes to progression of glomerular injury. As the deletion of only Hdac1 or Hdac2 in podocytes did not significantly improve glomerular lesions (data not shown), we tested whether loss of both HDAC1 and HDAC2 in podocytes mitigates the progression of glomerular injury. We initially confirmed that tissue-specific excision of HDAC1 and HDAC2 in the doxycycline-inducible podocyte-specific Hdac1-and -/-mice had reduced NTS-induced albuminuria and glomerular lesions (Supplemental Figure 8, A and B) . Next, to elucidate a role of EGR1 upregulation in podocyte injury, we examined F-actin staining patterns in primary podocytes and TUNEL staining in Tln1 fl/fl Pod-rtTA TetO-Cre mice with doxycycline, as increased EGR1 expression has been shown to regulate the actin cytoskeleton and induce cell apoptosis (35) (36) (37) (38) . Loss of podocyte-associated EGR1 expression or VPA treatment resulted in stabilization and maintenance of actin stress fibers after LPS treatment (for 6 hours) and PS treatment (for 1 hour) in comparison with controls ( Figure 9A , quantified in B-D; and Supplemental Figure 7A , quantified in C). Conversely, the overexpression of EGR1 in LPS-and VPA-treated control primary podocytes resulted in loss of actin stress fibers (Supplemental Figure 7B, quantified in D) . Furthermore, VPA treatment ameliorated LPS-induced cell spreading (increased cell surface area), while the overexpression of EGR1 in LPS-and VPA-treated control primary podocytes resulted in increased cell spreading ( Figure 9E ). VPA therapy also mitigated podocyte loss in comparison with untreated doxycycline-induced Tln1 fl/fl Pod-rtTA TetO-Cre mice (Supplemental Figure 7E ). However, TUNEL staining in kidneys 2 weeks after completion of doxycycline revealed apoptotic cells (TUNELpositive cells) in the tubular segments but not in podocytes (stained with WT1) (Supplemental Figure 7F) , suggesting that VPA treatment may protect podocytes by stabilizing the actin cytoskeleton and preventing other forms of programmed cell death.
VPA treatment improves decline of estimated glomerular filtration rate in proteinuric patients. To support the hypothesis that HDAC inhibition may also be a potent therapeutic strategy against human proteinuric kidney disease, we next interrogated the Veterans Aging Cohort Study. Among 122,870 veterans participating in the Study and eligible for analysis, the median (IQR) duration of follow-up was 9.0 (4.7-13.2) years. The mean rate of decline in estimated glomerular filtration rate (eGFR) was -0.94 (standard error 0.007) ml/1.73 m 2 /yr, which is consistent with several large, US population-based studies (39, 40) . Veterans exposed to VPA were slightly younger than those who were not exposed. They also had higher baseline eGFR and were less likely to be infected with HIV or HCV. They were more likely to be diabetic and to have hypertension, and bore a strikingly higher rate of psychiatric comorbidities, with fully 76.5% of those in the VPA group carrying a diagnosis of bipolar disorder compared with 21.4% of those in the unexposed group (Supplemental Table 4 ). Exposure to VPA (n = 2269) was associated with a significantly attenuated rate of decline in eGFR, with an unadjusted mean annual change in eGFR of -0.61 (0.07) ml/1.73 m /yr after the initiation of VPA (P < 0.0001) ( Figure 10B) .
Next, we analyzed the patients stratified by proteinuria. Among the patients with no or mild proteinuria (1+ or less on urine dipstick), the unadjusted mean yearly decline in eGFR was -0.92 (0.007) ml/1.73 m 2 /yr in the patients not receiving VPA, compared with -0.61 (0.07) ml/1.73 m 2 /yr in those receiving VPA ( Figure 10C ). In the patients with heavy proteinuria (2+ or more on urine dipstick), the unadjusted mean yearly decline in eGFR was -2.5 (0.05) ml/1.73 m 2 /yr in patients not receiving VPA, compared with -0.56 (0.66) ml/1.73 m 2 /yr in those receiving VPA ( Figure 10D ). After full adjustment, this effect modification by proteinuria was statistically significant at P = 0.02, suggesting that the beneficial effect of VPA is more pronounced in patients with worse proteinuria.
These results were robust to multiple sensitivity analyses. After exclusion of all patients who ever received lithium (a known nephrotoxic agent that is used for similar indications to VPA in this population), the protective effect of VPA and the interaction between VPA benefit and proteinuria were maintained 
Discussion
For the last 20 years, the mainstay of treatment of proteinuric kidney diseases that often lead to CKD has been to block the renin-angiotensin axis (41). However, various kinds of renin-(P = 0.008 and P = 0.07, respectively). Analyses that examined the effects of the comparator agents lamotrigine, carbamazepine, and levetiracetam revealed no protection of eGFR associated with exposure ( Figure 11, A-D) . investigators have also shown that following podocyte injury, HDAC4 and HDAC9 expression is increased, inhibiting autophagy, and reducing nephrin and podocin expression, respectively (50, 51) . Therefore, further studies examining each HDAC protein and the relationship between HDAC families in the pathogenesis of glomerular disease progression are required. Through our microarray analysis, we also determined that one of the likely targets regulated by HDAC1 and HDAC2 is a transcription factor, EGR1. Genetic loss of Egr1 on a Tln1 fl/fl Pod-rtTA TetO-Cre mouse background also reduced albuminuria and the progression of kidney disease, mimicking what was observed when these mice were treated with VPA. EGR1, one of the immediateearly response genes, was upregulated following several stimuli, such as growth factors and oxygen deprivation (52) (53) (54) . Several studies have demonstrated that EGR1 upregulation induces mesangial cell proliferation, kidney interstitial fibrosis through the TGF-β signaling pathway, and cellular apoptosis in cancer cells (55) (56) (57) (58) (59) . EGR1 upregulation may also be important for progression of glomerular disease not only in podocytes but also in other cell types. Interestingly, HDAC inhibitors have been shown to activate EGR1 in other cell types, suggesting cell-specific differences in regulation. These findings motivate further analysis to understand the role of EGR1 expression in the progression of glomerular diseases by use of cell-specific conditional Egr1-knockout mice (60-62).
In our results, HDAC inhibitors decreased CREB phosphorylation induced by LPS or PS in control podocytes, which resulted in reduced CREB binding to Egr1 promoter. It has been shown that kinases such as PKA, PKC, CaMK, ERK, AKT, and PTEN can regulate CREB phosphorylation (63) (64) (65) (66) (67) (68) . Previous studies also revealed that HDAC inhibitors increase PTEN expression in 293T cells (69) , but further studies will be needed to elucidate the link between PTEN and CREB phosphorylation following HDAC inhibition.
Lastly, a strong benefit of VPA in reducing loss of eGFR was demonstrated in a large longitudinal cohort of patients taking this medication for nonrenal indications. The findings were particularly robust in patients with proteinuria, in whom VPA administration was associated with significantly preserved kidney function over many years. Though observational data are subject to confounding by indication, these results are strengthened by the fact that VPA is not used in the management of kidney disease nor is the medication dose-adjusted among those with worse kidney function. Though our observational results were consistent across multiple subanalyses and sensitivity analyses, observational data cannot infer causation, and residual confounding may explain some of the observed effects. However, the lack of effect seen in analyses of non-HDAC inhibitor comparator agents may attenuate this concern. In addition, the Veterans Aging Cohort Study is predominantly male, limiting generalizability of these findings to other populations, while some patients may have obtained medications outside the Veterans Affairs system, which may lead to misclassification bias. Yet this would tend to bias our results toward the null.
In conclusion, we establish that HDAC1 and HDAC2 activation plays an important role in progression of glomerular disease through EGR1 upregulation. Treatment with VPA not only improved kidney function in proteinuric mice, but also ameliorated angiotensin system inhibitors have been shown to have only a marginal beneficial effect on progression of proteinuria and CKD. The increasing global prevalence of ESKD indicates the need for novel therapies for proteinuric kidney diseases (4, 42) . Therefore, in this study, we aimed to uncover novel molecular pathways that are potential targets for therapeutic intervention. From our unbiased screen using microarray data from injured mouse glomeruli, we identified phosphorylated-CREB-induced upregulation of EGR1 that may be governed by increased HDAC1 and HDAC2 activation resulting in foot process effacement. Inhibition by HDAC inhibitors protected podocytes and mitigated the progression and damage of the glomerular filtration barrier (Figure 12 ).
VPA is a common oral medication that has been in existence for close to 40 years, for the treatment of neurologic and psychiatric diseases (43) . Our initial decision to pursue VPA following our bioinformatics analysis was based on the drug's favorable side effect profile in relation to the stigmata of ESKD, which is a critical attribute in entertaining treatment options. Treatment with VPA, a class I HDAC inhibitor, as well as SAHA, an FDA-approved pan-HDAC inhibitor, strikingly improved both the progression of kidney disease, and VPA treatment improved the lifespan in 2 lines of transgenic mice that died as a result of kidney failure. Previous studies have shown that HDACs promote progression of glomerular disease as well as kidney fibrosis through the TGF-β signaling pathway (44) (45) (46) . It has been shown that HDAC inhibitors improve adriamycin-induced glomerular injury through downregulation of profibrotic and inflammatory genes (47) , and combinations of HDAC inhibitor and renin-angiotensin system inhibitors improve kidney function in an HIV-associated glomerular injury model (8) . However, HDAC inhibitors' sites of action have remained elusive. Through our study, we speculate that inhibition of HDAC1 and HDAC2 activity specifically in podocytes is critical, as genetic ablation of Hdac1 and Hdac2 strikingly mitigated the progression of albuminuria and glomerulosclerosis. Deletion of either podocyte Hdac1 or Hdac2 alone did not significantly improve proteinuria or kidney failure in Tln1 fl/fl Pod-rtTA TetO-Cre mice. This lack of improvement is likely due to the redundant and compensatory roles of HDAC1 and HDAC2, as previous studies have shown that knockdown or deletion of either Hdac1 or Hdac2 alone is not sufficient to block histone acetylation (48, 49 ). Other Urine albumin was quantified in duplicates using an Albumin ELISA Quantitation kit according to the manufacturer's protocol (Bethyl Laboratories Inc.). Plasma and urine creatinine were measured in duplicate for each sample at the time points above using a colorimetric quantification kit (Bioassay Systems) at an absorbance of 490 nm (Microplate Reader; Bio-Rad).
Cell culture. Isolation of podocytes from day 1-3 control and Egr1
-/-Pod-Cre Rosa-DTR flox pups was performed as described previously (72) . Medium including diphtheria toxin (Sigma-Aldrich) was changed every other day 2 days after seeding of glomerular cells as previously described (72) . Podocytes in culture were pretreated with VPA (0.5
TetO-Cre mice, respectively. All generated mice were backcrossed more than 10 times before experiments. For podocyte injury models in vivo, nephrotoxic serum (NTS) (150 μl) was injected i.v. 5 days after adjuvant injection i.p. in control C57BL/6 mice at 8 weeks of age with or without i.p. VPA or SAHA administration 3 days after NTS injection.
For another podocyte injury model, adriamycin (Sigma-Aldrich) (15 mg/kg body weight) was injected i.v. in 8-week-old BALB/c mice (The Jackson Laboratory), and VPA or SAHA was administered 7 days after adriamycin injection for 3 weeks. Biochemical measurements, urine albumin, urine creatinine, and plasma creatinine. Mouse urine samples were collected at various ages. culated as previously described (73) . Z ratio of each gene was calculated by comparison of its expressions in different samples. The genes with absolute Z ratio value greater than 1.96 were identified as differentially expressed genes. These genes were shown in a 2-way hierarchical heatmap. Red and blue indicate up-and downregulated genes, respectively. Upstream protein networks and pharmaceutical agents associated with the differentially expressed genes from control and Tln1 fl/fl Pod-rtTA TetO-Cre mouse glomerulus microarray data sets were identified using Expression2Kinases (X2K) software (74) . Briefly, X2K identified potential transcription factors regulating the differentially expressed genes using the ChIP-X Enrichment Analysis database. The transcription factors are then connected using known protein interactions, constructing a transcriptional regulatory subnetwork. Finally, pharmaceutical agents are identified that may reverse changes of differentially expressed genes in this subnetwork. mM) or SAHA (1 μM) and treated with 70 μg/ml lipopolysaccharide (LPS) (Sigma-Aldrich) or 20 μg/ml protamine sulfate (PS) (SigmaAldrich) at the designated time points.
Microarray of glomerular DNA and bioinformatics analysis. Glomeruli were isolated in control and Tln1 fl/fl Pod-rtTA TetO-Cre mice 2 weeks after completion of doxycycline induction with or without VPA treatment. The glomerular RNA was isolated by RNeasy kit (Qiagen) and was sent to the Yale Center for Genome Analysis for microarray on the Affymetrix Mouse Genome 430 2.0 platform. We used the R Bioconductor package to analyze the raw microarray gene expression data sets. Background for each data set was corrected using the RMA algorithm in the limma package. Probes were mapped to gene symbols using the annotation file downloaded from the Affymetrix website; probes with no annotation were discarded. The expression values in biological replicates were averaged. Z score for each gene was cal- with a SimpleChIP Kit according to the manufacturer's protocol (Cell Signaling Technology). Coprecipitated DNA and input DNA were quantified by reverse transcriptase PCR calculating as the ratio of PCR signal from coprecipitated DNA to that from input DNA. As the mouse Egr1 gene promoter contains 5 serum response elements (SREs) and 2 cAMP response elements (CREs) and the CREs and the first 2 SREs are close, we generated primers in the mouse Egr1 promoter as follows: primer set 1 (for CREs and the first 2 SREs) forward 5′-TTTCCAGGAG-CCTGAGCGC-3′, reverse 5′-CCCGAATCGGCCTCTATTTCA-3′; primer set 2 (for the other SREs) forward 5′-CCGACCCGGAAACGC-CATAT-3′, reverse 5′-TCCTCCCAGAGCCGGAAA-3′. HDAC1 and HDAC2 activity assays. Mouse glomeruli were isolated, followed by podocyte enrichment by sieving through a 40-μm cell strainer. Nuclear protein was extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). Total HDAC activity was measured using an Epigenase HDAC Activity/ Inhibition Direct Assay Kit according to the manufacturer's protocol (Epigentek). Each HDAC1 and HDAC2 activity was measured using an HDAC1 or HDAC2 Immunoprecipitation & Activity Assay Kit, respectively, according to the manufacturer's protocol (BioVision).
Kidney histology and quantification. Mice were anesthetized by i.p. injection of ketamine and xylazine followed by perfusion fixation with 4% paraformaldehyde with or without 2 % glutaraldehyde through the left ventricle. Sections were stained for H&E, periodic acid-Schiff, and Masson's trichrome staining by the Yale Pathology Core Tissue Services. To evaluate glomerulosclerosis and interstitial fibrosis, kidney sections with Masson's trichrome staining were assessed as previously Quantitative PCR analysis. Total RNA was extracted from the primary podocytes or isolated glomeruli using Trizol (Thermo Fisher Scientific). The RNA concentration was measured by spectrophotometry (Nanodrop Technologies). The RNA (1 μg) was used for reverse transcription by a high-capacity cDNA Synthesis Kit according to the manufacturer's instructions (Applied Biosystems). The quantitative PCR amplifications were performed using Power SYBR Green PCR Master Mix (Applied Biosystems) with a 7300 AB real-time PCR machine (Applied Biosystems).
Immunoblotting. Primary podocytes or isolated glomeruli were lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.6), 500 mM NaCl, 0.1% SDS, 0.5 % deoxycholate, 1 % Triton X-100, 0.5 mM MgCl 2 , 1 mM Na 3 VO 4 , 50 mM NaF, 1 mM PMSF, protease inhibitor cocktail (Roche Diagnostics), and phosphatase inhibitor cocktail (MilliporeSigma). Protein concentrations were quantified using the Bio-Rad protein assay. Equal amounts of lysates were separated by SDS-PAGE and transferred on PVDF membranes (EMD Millipore Corp.). The membrane was blocked with 5% nonfat milk (American Bio) or 3% BSA (Sigma-Aldrich) in Tris-buffered saline and Tween-20 (TBS-T) and incubated with the appropriate primary antibody at 4°C overnight. After 3 washes with TBS-T, the appropriate peroxidaselabeled anti-IgG secondary antibody (Millipore) was added and signals detected using enhanced chemiluminescence reagents (Bio-Rad) and exposed with Odyssey (LI-COR Biosciences). For quantification, densitometry was performed using ImageJ software (NIH).
ChIP assay. Primary podocytes were cross-linked by 1 % formaldehyde, and ChIP assay was performed using CREB or SRF antibody C and D) The slope of eGFR decline among patients with no or mild proteinuria (1+ or below on urine dipstick) (C) and with heavy proteinuria (>2+ on urine dipstick) (D) with or without VPA. *P-for-interaction = 0.02. All graphs reflect eGFRs adjusted for age, sex, race, baseline eGFR, HCV, HIV, diabetes, hypertension, congestive heart failure, liver disease, bipolar disorder, depression, post-traumatic stress disorder, prior stroke, epilepsy, and headache. The visualized slopes reflect eGFR at the mode of categorical covariates and the mean of continuous covariates. grouped into 4 major classes, which were used for scoring as described previously (type A: more than 90% of cell area filled with thick cables; type B: at least 2 thick cables running under nucleus and rest of cell area filled with fine cables; type C: no thick cables, but some cables present; type D: no cables visible in the central area of the cell) (20, 78) . One hundred primary podocytes from each mouse were analyzed in 3 independent experiments. Cell spreading. Following overexpression of GFP or GFP-EGR1 in control podocytes, cells were detached by trypsin digestion. The cell suspension was placed on collagen I-coated coverslips, and the cells were treated with LPS (3 hours) with or without VPA. The primary podocytes were fixed with 4% paraformaldehyde and stained with GFP and phalloidin. The cell surface area was measured in GFPpositive primary podocytes using NIH ImageJ software.
Human study. Participants in the Veterans Aging Cohort Study (VACS) were considered for enrollment. The VACS is a longitudinal cohort study of 141,686 HIV-positive veterans and an age/race/ site-matched sample of uninfected controls (79) . For the present analysis, we included VACS participants with at least 2 outpatient creatinine values measured at least 1 year apart to allow for calculation of a slope of eGFR. GFR was estimated using the CKD-Epi formula (80) . VPA exposure during a creatinine interval was defined as the presence of a VPA prescription for more than 50% of the days between 2 consecutive creatinine measurements.
A patient time period (bounded by sequential creatinine measurements) was classified as "exposed to VPA" if the patient had an active prescription for VPA for at least 50% of that period.
described (75) . The number of foot processes was divided by the total length of glomerular basement membrane regions in each electron microscopic image (76) . In all histological analysis, 3 different mice were used in independent experiments.
Immunofluorescence staining. Primary podocytes on collagen I-coated coverslips were washed by PBS and fixed with 4% paraformaldehyde for 15 minutes. The cells were permeabilized with 0.1% Triton X in PBS for 5 minutes, followed by blocking with 3% BSA in PBS for 1 hour. For human kidney biopsy samples, paraffin-embedded kidney sections were deparaffinized by xylene following hydration by ethanol. For both human and mouse kidney sections, antigen retrieval was induced by microwave following washing with PBS, and kidney sections were blocked with 3% BSA in PBS. Immunostaining was performed with primary antibodies overnight at 4°C, followed by Alexa Fluor 488-and/or Alexa Fluor 594-conjugated secondary antibodies, and then cells were washed with PBS and mounted with Slowfade (Invitrogen). TUNEL staining was performed using an In Situ Cell Death Detection Kit according to the manufacturer's protocol (Roche). In each immunofluorescence staining, 3 different mice or podocytes were used. Images were taken by an Andor CSU-WDi spinning disc confocal microscope equipped with a Nikon Ti-E CFI Plan Apochromat Lambda ×60 oil immersion objective for immunofluorescence analysis, and images were processed using NIH ImageJ software (version 1.51H) or Adobe Photoshop CS 2014. For quantification of podocyte number, WT1-positive nuclei were counted in each glomeruli (77) . For quantification of changes in actin cytoarchitecture of primary podocytes, podocytes stained with phalloidin were C and D) The slope of eGFR decline among patients with no or mild proteinuria (1+ or below on urine dipstick) (C) and with heavy proteinuria (>2+ on urine dipstick) (D) with or without comparator drugs. All graphs reflect eGFRs adjusted for age, sex, race, baseline eGFR, HCV, HIV, diabetes, hypertension, congestive heart failure, liver disease, bipolar disorder, depression, post-traumatic stress disorder, prior stroke, epilepsy, and headache. The visualized slopes reflect eGFR at the mode of categorical covariates and the mean of continuous covariates. jci.org Volume 129
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Statistical analysis was performed by GraphPad Prism 7 software. A P value less than 0.05 was considered statistically significant. For human data, statistical significance was determined with a 2-sided P value less than 0.05 for primary effects and less than 0.10 for interaction tests. Analyses were performed in Stata v15.0 (StataCorp) and SAS version 9.4 (SAS Institute). Study approval. The Yale University IACUC approved all animal experiments, and the Veterans Affairs IRB (West Haven, CT) approved the analysis of VACS data. All work was carried on in accordance with the principles and procedures outlined in the NIH guidelines for the care and use of experimental animals.
We compared covariates across groups using Student's t test or χ 2 tests as appropriate. The primary statistical analysis used a mixedeffects model with random slopes and random intercepts. Time periods were bounded by creatinine measurements. To estimate the slope of eGFR, time interaction terms were included in the model. The fixed component of the model was used to assess between individual effects of VPA, while the random component was used to assess within individual effects. All models were adjusted for baseline eGFR, age, sex, race, presence of HIV, presence of hepatitis C, diabetes, hypertension, congestive heart failure, liver disease, bipolar disorder, depression, post-traumatic stress disorder, prior stroke, epilepsy, and headache. We ascertained comorbidities using ICD-9 codes (81). The predefined comparator agents were lamotrigine, carbamazepine, and levetiracetam. Owing to sparse numbers for these agents, exposure to these medications was combined into a single "comparator medication exposure" variable. Lithium use was coded as an "ever exposed" versus "never exposed" variable. Patients with any lithium exposure were excluded from a sensitivity analysis to ensure that the observed benefit of VPA administration was not due to the withdrawal of lithium.
Data availability. The microarray data used in this study were deposited in the NCBI's Gene Expression Omnibus database under accession code GSE112116.
Statistics. Data are displayed as the mean ± SEM. The number of replicates for each experiment is shown in Methods or the figure legends. Statistical differences between 2 groups were evaluated by a 2-tailed t test. Multiple-group comparisons were evaluated using 1-way ANOVA followed by Dunnett's multiple-comparisons tests. 
